Fibrates, Hypertriglyceridemia, and CVD Risk: Where Do We Stand After the PROMINENT Trial for Triglyceride Lowering?

Area of Science:

• Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Hypertriglyceridemia (HTG) is a significant risk factor for cardiovascular disease (CVD).
• Recent research investigates triglyceride-lowering therapies for CVD risk reduction in HTG patients.
• Patients with HTG often have other co-existing risk factors for CVD.

Purpose of the Study:

• To evaluate recent clinical trials on managing hypertriglyceridemia (HTG).
• To assess the impact of triglyceride reduction on cardiovascular disease (CVD) outcomes in HTG patients.

Main Methods:

• Review of randomized clinical trials in hypertriglyceridemic patients.
• Analysis of outcomes from treatments including pemafibrate and icosapent ethyl.
• Consideration of background statin therapy in trial participants.

Main Results:

• Pemafibrate failed to reduce cardiovascular events despite significant triglyceride reduction (25-35%).
• Icosapent ethyl demonstrated CVD event reduction with more modest triglyceride reduction (~20%).
• Divergent results suggest triglyceride lowering alone is insufficient for CVD risk mitigation.

Conclusions:

• Therapeutic effectiveness in HTG patients may stem from suppressing atherogenic properties, not just lowering triglycerides.
• Triglyceride reduction alone is insufficient to offset CVD risk in hypertriglyceridemic patients.
• Further research is needed to understand the mechanisms behind CVD risk reduction in HTG.